Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Data points received from the doctors/ gastrologist:
3.1.3 Data points received from the manufacturer/ pharmaceutical companies:
3.1.4 Data points received from Hospitals, Clinics:
3.1.5 Secondary Research Methodology
3.1.6 Market Share Analysis
3.1.7 Trade Analysis
3.1.8 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of anxiety (Impact Weightage: 37%)
4.2.2 Strong clinical pipeline (Impact Weightage: 35%)
4.2.3 Increasing prevalence of depression (Impact Weightage: 28%)
4.3 Restraints
4.3.1 Strict FDA regulations (Impact Weightage: 60%)
4.3.2 Unsatisfactory effectiveness of the treatment (Impact Weightage: 40%)
4.4 Opportunity
4.5 Mega Trends
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 Research and Development
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
5.2 Porters Five Forces
5.2.1 Threat of New Entrants (Medium to High)
5.2.2 Bargaining power of suppliers (Medium)
5.2.3 Threat of Substitutes (Medium to High)
5.2.4 Bargaining Power of Buyers (Medium)
5.2.5 Intensity of Rivalry (Medium to High)
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
5.6 Merger and Acquisition Landscape
6 Americas IBS Treatment Market, By Type
6.1 Introduction
6.2 IBS-D
6.3 IBS-C
6.4 IBS-M
7 Americas IBS Treatment Market, By Drug Type
7.1 Introduction
7.2 Lubiprostone
7.3 Linaclotide
7.4 Eluxadoline
7.5 Rifaximin
7.6 Alosetron
8 Americas IBS Treatment Market, By End User
8.1 Introduction
8.2 Hospitals
8.3 Clinics
8.4 Research laboratories
9 Americas IBS treatment By Region
9.1 Introduction
9.1.1 North America
9.1.1.1 U.S.
9.1.1.2 Canada
9.1.2 South America
10 Company Landscape
11 Company Profiles
11.1 Allergan Plc
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Sucampo Pharmaceuticals
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Ironwood Pharmaceuticals, Inc.
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 Astellas Pharma Inc.
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Valeant Pharmaceuticals
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Abbott Laboratories
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Synergy Pharmaceuticals, Inc.
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments
11.8 Ardelyx, Inc.
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Nestle
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.1 Sebela Pharmaceuticals
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 Probi
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Strategy
11.11.5 Key Developments
11.12 Alfasigma USA, Inc.
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Strategy
11.12.5 Key Developments
12 Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.1.2 Unmet Needs
12.2 Key Companies to Watch
13 Appendix
13.1 Discussion Blue Print